Advanced Lung Cancer: A Year in Review

EP. 1: Work-Up and Management of Nondriver Metastatic Lung Cancer

April 13th 2020

EP. 2: Therapy Approach for PD-L1 Over 50% Lung Cancer

April 13th 2020

EP. 3: Progression on Immunotherapy: Treatment Approach

April 13th 2020

EP. 4: PD-L1 Less Than 49%: Available Treatments

April 13th 2020

EP. 5: Immunotherapy and Brain Metastatic Lung Cancer

April 13th 2020

EP. 6: How Long to Continue Immunotherapy

April 13th 2020

EP. 7: The IMpower150 Regimen

April 13th 2020

EP. 8: When to Use the CheckMate-227 Regimen

April 13th 2020

EP. 9: Lung Cancer Molecular Testing Protocol

April 13th 2020

EP. 10: Upfront Targeted Treatment Approach

April 13th 2020

EP. 11: Oligometastatic and Small Cell Transformation Management

April 13th 2020

EP. 12: When to Re-Treat with Osimertinib

April 13th 2020

EP. 13: ALK-Rearranged & MET Exon 14 NSCLC Treatment Options

April 13th 2020

EP. 14: Brain Metastatic NSCLC: Targeted Therapy Approach

April 13th 2020

EP. 15: Unresectable Stage III Lung Cancer Management

April 13th 2020

EP. 16: Stage III NSCLC: When to Start Durvalumab

April 13th 2020

EP. 17: Stage III NSCLC Progression Treatment Strategy

April 13th 2020

EP. 18: Small-Cell Lung Cancer: The IMpower133 and CASPIAN trials

April 13th 2020

EP. 19: Limited-Stage SCLC: Is Immunotherapy an Option?

April 13th 2020

EP. 20: The Future of Lung Cancer Management

April 13th 2020

x